Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., filed a Form 4 on September 21, 2026, reporting an option exercise and the sale of common stock on September 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercised: Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share on September 17, 2026.
  • Shares sold: A total of 5,000 shares were sold across three separate transactions at weighted average prices of $50.0312, $50.7089, and $51.482.
  • Remaining ownership: Following the transactions, Collins directly holds 25,000 shares, all of which the filing identifies as RSUs, plus 106,268 stock options.
  • Rule 10b5-1 plan: The option exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Collins on October 19, 2025.
  • Multi-trade executions: Each of the three sale transactions was executed in multiple trades, with per-share prices ranging from $49.305 to $51.675 across all three blocks combined.

Enliven Therapeutics CMO Option Exercise and Share Sale Details

According to the filing, Collins exercised a stock option covering 5,000 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) common stock on September 17, 2026, at an exercise price of $2.48 per share. The filing notes that all shares subject to this option were "fully vested and exercisable as of the date hereof." The option carries an expiration date of June 17, 2031, and the price of the derivative security upon exercise is reported as $0.

On the same date, Collins disposed of 5,000 shares across three sale transactions. The first covered 2,916 shares at a weighted average price of $50.0312, with individual trade prices ranging from $49.305 to $50.30. The second covered 1,844 shares at a weighted average price of $50.7089, with prices ranging from $50.3099 to $51.26. The third covered 240 shares at a weighted average price of $51.482, with prices ranging from $51.365 to $51.675. The filing states that Collins will provide full information on individual trade prices upon request by the SEC staff, the issuer, or a security holder.

After all reported transactions, Collins directly holds 25,000 shares of common stock, which the filing identifies as RSUs. The filing notes that "each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU." All activity was conducted under a Rule 10b5-1 plan adopted on October 19, 2025. The Form 4 was signed by Ben Hohl, by power of attorney, on September 21, 2026.

What Was Disclosed

Enliven Therapeutics Chief Medical Officer Helen Louise Collins reported exercising 5,000 stock options at $2.48 and selling the resulting shares in three transactions on September 17, 2026, leaving her with 25,000 RSUs and 106,268 remaining stock options.